AIMEDBIO

PR

Press Release

AimedBio Entered into a Global Collaboration and Licensing Agreement with Boehringer Ingelheim
2025.10.15
  • - AimedBio has signed a global licensing agreement with Boehringer Ingelheim for a next-generation antibody-drug conjugate (ADC) candidate.
  • - The deal is valued at up to USD 991 million (approximately KRW 1.4 trillion), including an upfront payment, development, regulatory and commercial milestones, and tiered sales royalties.
  • - Under the agreement, Boehringer Ingelheim obtains worldwide development and commercialization rights to AimedBio’s novel ADC targeting solid tumors, including KRAS-mutant cancers.
  • - The candidate incorporates a Topo1 inhibitor payload and is designed to deliver potent anti-tumor activity with high tumor selectivity. A Phase 1 (First-in-Human) trial is planned for 2026.

    •  

  • - The agreement further validates AimedBio’s proprietary precision antibody and ADC platform, strengthening its global partnership portfolio ahead of its planned KOSDAQ IPO.

    Link: https://www.globenewswire.com/news-release/2025/10/15/3167043/0/en/Boehringer-Ingelheim-advances-cancer-antibody-drug-conjugate-portfolio-with-asset-from-AimedBio.html
    • LIST